Quarterly ResultAug 6, 2026, 07:08 AM
Amylyx Q2 Net Loss $43.4M; LUCIDITY Data Expected Soon
AI Summary
Amylyx Pharmaceuticals reported a Q2 2026 net loss of $43.4 million, or $0.39 per share. The company announced the completion of the final study visit for the last participant in its pivotal Phase 3 LUCIDITY trial for avexitide, with topline data expected in late August or early September 2026. Amylyx anticipates its cash runway will fund operations into 2028.
Key Highlights
- Last participant completed final study visit in Phase 3 LUCIDITY trial for avexitide.
- Topline data for LUCIDITY trial anticipated in late August or early September 2026.
- Q2 2026 net loss was $43.4 million, compared to $41.4 million in Q2 2025.
- Q2 2026 net loss per share was $0.39, compared to $0.46 in Q2 2025.
- Cash, cash equivalents, and short-term investments totaled $250.8 million at June 30, 2026.
- Cash runway expected to fund operations into 2028.
- Initiated U.S. Expanded Access Program for avexitide in May 2026.
- Second research collaboration with Gubra A/S for rare endocrine disease initiated.
Price Impact
More from AMLX